![]() Harmonization of infliximab and anti-infliximab assays facilitates the comparison between originators and biosimilars in clinical samples. Gils A, Van Stappen T, Dreesen E, et al.United States Food and Drug Administration Biosimilar Guidance webpage.Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn’s disease. Steenholdt C, Ainsworth MA, Tovey M, et al.Immunogenicity of anti-TNF-α biotherapies, I: individualized medicine based on immunopharmacological evidence. Immunogenicity assessment of tumor necrosis factor antagonists in the clinical laboratory. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases: a systematic review and meta-analysis. Thomas SS, Borazan N, Barroso N, et al.Assessing response and loss of response to biological therapies in IBD. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease. Feuerstein JD, Nguyen GC, Kupfer SS, et al.Guidelines of care for the management of psoriasis and psoriatic arthritis, section 1: overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Menter A, Gottlieb A, Feldman SR, et al. ![]() 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |